Monopar Therapeutics Files 2025 Proxy Statement

TL;DR

Monopar Proxy filed. Vote on directors & auditors June 17.

AI Summary

Monopar Therapeutics Inc. filed its definitive proxy statement on April 30, 2025, for its annual meeting of stockholders scheduled for June 17, 2025. The filing details the company's corporate governance, executive compensation, and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of independent auditors.

Why It Matters

This filing provides shareholders with crucial information to make informed voting decisions on company leadership and important corporate matters, impacting the company's strategic direction.

Risk Assessment

Risk Level: low — This is a routine annual filing (DEF 14A) that outlines standard corporate governance and shareholder voting matters, not indicating new or unusual risks.

Key Players & Entities

• Monopar Therapeutics Inc. (company) — Registrant
• June 17, 2025 (date) — Annual Meeting Date
• April 30, 2025 (date) — Filing Date

FAQ

From the Filing

0001437749-25-013824.txt : 20250430 0001437749-25-013824.hdr.sgml : 20250430 20250430153455 ACCESSION NUMBER: 0001437749-25-013824 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20250617 FILED AS OF DATE: 20250430 DATE AS OF CHANGE: 20250430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 25894518 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 DEF 14A 1 mnpr20250418_def14a.htm FORM DEF 14A mnpr20250418_def14a.htm false 0001645469 false false false DEF 14A 0001645469 2024-01-01 2024-12-31 thunderdome:item xbrli:pure 0001645469 us-gaap:EmployeeStockOptionMember 2024-12-31 iso4217:USD iso4217:USD xbrli:shares     Table of Contents     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 14A INFORMATION   Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box:   ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240.14a-12     MONOPAR THERAPEUTICS INC.   (Name of Registrant as Specified in Its Charter)   (Name of Person(s) Filing Proxy Statement, if other than the Registrant)   Payment of Filing Fee (Check the appropriate box):   ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a–6(i)(1) and 0–11.       Table of Contents         NOTICE OF ANNUAL MEETING OF STOCKHOLDERS   To Be Held on June 17, 2025, at 10:00am Central Time   Dear Stockholder:   You are cordially invited to attend the Annual Meeting of Stockholders of Monopar Therapeutics Inc., a Delaware corporation (the “ Company ”), which will be held on June 17, 2025, at 10:00am Central Time at the Company’s headquarters at 1000 Skokie Blvd., Wilmette, IL 60091 (the “ Annual Meeting ”). Only stockholders who held stock at the close of business on the record date, April 25, 2025, may vote at the Annual Meeting, including any adjournment or postponement thereof.   At the Annual Meeting, you will be asked to consider and vote upon: (1) the election of six directors named herein to our Board of Directors to serve until our next annual meeting of stockholders or until their respective successors are duly elected and qualified; (2) the compensation of our named executive officers (“NEOs”) on an advisory, non-binding basis; (3) the frequency of future advisory votes on the compensation of our NEOs on an advisory, non-binding basis; and (4) the ratification of the selection of BPM LLP as our independent registered public accounting firm for the year ending December 31, 2025. No other items of business are expected to be considered, and no other director nominees will be entertained, at the Annual Meeting.   The accompanying Proxy Statement more fully describes the details of the business to be conducted at the Annual Meeting. After careful consideration, our Board of Directors has unanimously approved the proposals and recommends that you vote: (1) “FOR” each of the six director nominees; (2) “FOR&